Headlands Technologies LLC Takes $6.25 Million Position in Gilead Sciences, Inc. $GILD

Headlands Technologies LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, Holdings Channel reports. The fund purchased 49,478 shares of the biopharmaceutical company’s stock, valued at approximately $6,251,000. Gilead Sciences makes up 0.7% of Headlands Technologies LLC’s holdings, making the stock its 27th biggest position.

A number of other institutional investors also recently bought and sold shares of the stock. Paulson Wealth Management Inc. increased its position in Gilead Sciences by 1.8% during the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 67 shares during the last quarter. Essex Financial Services Inc. raised its stake in shares of Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after acquiring an additional 71 shares during the period. Davidson Trust Co. lifted its holdings in shares of Gilead Sciences by 4.1% in the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after acquiring an additional 74 shares during the last quarter. Alpha Cubed Investments LLC lifted its holdings in shares of Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after acquiring an additional 75 shares during the last quarter. Finally, Financial Connections Group Inc. boosted its stake in shares of Gilead Sciences by 30.2% during the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 76 shares during the period. 83.67% of the stock is currently owned by institutional investors.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA approved Bixlenvo, a once-daily single-tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. It is the first and only single-tablet option for patients on complex regimens who cannot use currently available alternatives, potentially expanding Gilead’s HIV franchise and supporting its longer-term lenacapavir strategy. Reuters FDA approval article
• Positive Sentiment: The European Commission approved Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients, strengthening Gilead’s oncology portfolio and adding a potential growth opportunity outside its core HIV business. EU Trodelvy approval article
• Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target of approximately $158. However, GILD’s strong multi-year advance may have raised expectations and limited the immediate upside from the Bixlenvo approval. Gilead valuation article
• Negative Sentiment: Director Anthony Welters sold 18,000 shares worth about $2.68 million, reducing his position by roughly 58%. The sale occurred under a pre-arranged Rule 10b5-1 plan, making it a limited bearish signal, but it may still weigh modestly on investor sentiment. SEC insider transaction filing

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $145.68 on Monday. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The firm has a market capitalization of $180.64 billion, a price-to-earnings ratio of -54.56 and a beta of 0.32. The stock has a 50 day moving average price of $134.25 and a 200 day moving average price of $136.51. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same period in the prior year, the business earned $2.01 EPS. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.5 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. Gilead Sciences’s dividend payout ratio is -122.85%.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Rothschild & Co Redburn cut their price target on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Weiss Ratings downgraded Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $133.00 to $155.00 in a research note on Monday, July 6th. Finally, Needham & Company LLC restated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Twenty-four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Insider Activity at Gilead Sciences

In other news, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the sale, the director owned 12,894 shares in the company, valued at approximately $1,916,306.28. The trade was a 58.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares of the company’s stock, valued at $1,459,771.32. The trade was a 33.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 90,000 shares of company stock worth $12,266,220 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.